Hormone Replacement Therapy Market Share Analysis Report, 2022-2030
The global Hormone Replacement Therapy market size was estimated at USD 20,462.9 million in 2021 and is expected to surpass around USD 35.80 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period 2022 to 2030.
Growth Factors:
The hormone replacement therapy (HRT) market is witnessing growth due to the factors such as the rising incidence of target diseases and the availability of long-acting hGH products. According to American Thyroid Association, around 12.0% of the U.S. population is estimated to suffer from thyroid during their lifetime. It also reported that approximately 20.0 million U.S. citizens have some form of thyroid disease.Several studies showed that people who are on HRT therapy are likely to have a low risk of COVID-19 infection and mortality rate.
A study led by the Oxford-Royal College of General Practitioners Research and Surveillance Centre studied 1.8 million medical records of women from 465 general practitioners and found 5,451 COVID cases linked with HRT (estrogen therapy treatment) witnessed a 78% reduction in infection and mortality rate. The male population tends to have a more severe infection and higher rates of hospitalization and mortality.
The increasing involvement of key players in the development of novel therapies is resulting in the introduction of new products in the market. For instance, in January 2022, Ascendis Pharma A/S received European Commission's market authorization for its drug SKYTROFA for the treatment of children and adolescents suffering from growth hormone disorders. This product is the first once-weekly treatment for growth hormone deficiency in the pediatric population.
Increasing awareness about hormone deficiency and disorders is expected to propel market growth. For instance, Child Growth Foundation is a UK-based non-government organization dedicated to supporting people living with rare growth hormone disorders. This organization provides information and support to patients, caregivers, & healthcare professionals to improve patients' quality of life.
However, the high cost associated with hormonal replacement therapy treatment may restrain the growth of the market. For instance, hormone replacement therapy injectable annually costs around USD 288 to USD 1,440 for insured patients and USD 480 to USD 4,800 for uninsured patients.
Report Scope of the Hormone Replacement Therapy Market
|
Report Coverage |
Details |
|
Market Size |
US$ 35.80 Billion by 2030 |
|
Growth Rate |
CAGR of 6.9% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, route of administration, disease type, and Region, |
|
Companies Mentioned |
Bayer AG; Pfizer Inc.; Merck & Co., Inc.; Viatris, Inc.; Novo Nordisk A/S; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Noven Pharmaceuticals, Inc.; ASCEND Therapeutics US, LLC.; AbbVie, Inc. |
Product Insights
Based on product, the HRT market is segmented into estrogen & progesterone replacement therapy, hGH replacement therapy, thyroid replacement therapy, parathyroid hormone replacement, and testosterone replacement therapy. The estrogen and progesterone replacement therapy segment held the highest market share of 53.15% in 2021. The dominance was attributed due to an increase in the number of women suffering from menopause. According to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause daily in the U.S.
The parathyroid hormone replacement segment is expected to witness the fastest growth during the forecast period owing to rising incidence and increasing product penetration. According to the National Organization for Rare Disease 2021 database, around 70,000 people in the U.S. are living with hypoparathyroidism. In the parathyroid hormone segment, only one product has been approved, i.e., Natpara.
Route of Administration Insights
Based on route of administration, the HRT market is segmented into oral, parenteral, transdermal, and others. The oral segment dominated the market in 2021 due to the high prescription rate and ease of administration. Most HRT products generally include pills & tablets.
The parenteral segment is expected to witness lucrative growth during the forecast period. An improvement in drug delivery through parenteral modes, such as pen-based drug delivery, is anticipated to improve patient compliance and facilitate ease of administration, driving the segment growth. Some of the popular products available in pen form include Genotropin Mixer Pen, Norditropin FlexPro Pen, and Humatrope HumatroPen.
Moreover, the launch of a new long-acting growth hormone injection is also expected to drive segment growth. For instance, in January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labour and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorder. This product is the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
Disease Type Insights
Based on disease type, the HRT market has been segmented into menopause, male hypogonadism, hypothyroidism, growth hormone deficiency, and hypoparathyroidism. The menopause segment dominated the market in 2021. This can be attributed to the owing to increase in the number of women suffering from menopause.
According to the UN's 2020 global estimates, 958 million women were aged 50 and above. By 2050, this number is expected to reach 1.65 million. Millions of women are likely to spend more than one-third of their lives after menopause in the future. However, menopause age varies based on various factors; natural factors, such as habitat and genetics, change the age of menopause in individuals to some extent.
The hypoparathyroidism segment is expected to witness significant growth during the forecast period owing to an increase in novel treatments and the introduction of products. For instance, in September 2020, Ascendis Pharma A/S showcased the TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. It also published the top-line results of the phase 2 clinical trial for TransCon PTH at the annual meeting. The drug is currently in phase 3 clinical trials. The approval and subsequent launch of this product will provide more options available for parathyroid hormone replacement.
Regional Insights
North America dominated the global hormone replacement therapy market with a share of 37.54% in 2021 and is anticipated to grow at a significant rate during the forecast period. Major product launches, collaborative agreements between manufacturers, and favorable reimbursement policies are among the factors responsible for the largest market share in the region. For instance, in August 2020, the U.S. FDA approved Sogroya (somapacitan-beco), an HGH replacement therapy product developed by Novo Nordisk A/S. This product is administered once a week through a subcutaneous route in adults diagnosed with growth hormone deficiency.
The Asia Pacific is estimated to be the fastest-growing region during the forecast period. As per the Journal of the North American Menopause Society (May 2022), the prevalence of vasomotor symptoms associated with menopause has been reported to range from 43% to 83% in women in East Asian countries. Thus, the growing number of women reaching menopause is expected to drive the demand for hormone replacement therapy in the region.
Some of the prominent players in the Hormone Replacement Therapy Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Hormone Replacement Therapy market
· Product
· Estrogen and Progesterone Replacement Therapy
· Human Growth Hormone (HGH) Replacement Therapy
· Thyroid Hormone Replacement Therapy
· Testosterone Replacement Therapy
· Parathyroid Hormone Replacement
· Route of Administration
· Oral
· Parenteral
· Transdermal
· Others
· Disease Type
· Menopause
· Hypothyroidism
· Male Hypogonadism
· Growth Hormone Deficiency
· Hypoparathyroidism
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Hormone Replacement Therapy Market Study:
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 List of Abbreviations
1.12 Objectives
1.12.1 Objective 1
1.12.2 Objective 2
1.12.3 Objective 3
1.12.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Variable Analysis
3.4.1 Market driver analysis
3.4.1.1 Rising prevalence of hormonal disorders and increasing number of patients undergoing hormone replacament therapy
3.4.1.2 Technological developments in drug delivery systems
3.4.1.3 Increasing R&D investments and rising awareness about hormone deficiency
3.4.2 Market restraint analysis
3.4.2.1 High cost of treatment
3.4.2.2 Risk of side effects
3.5 Industry Analysis Tools
3.5.1 Porter's five forces analysis
3.6 Industry Analysis Tools
3.6.1 PESTEL Analysis
3.7 Pipeline Analysis
Chapter 4 Hormone Replacement Therapy Market - Segment Analysis, by Product Type, 2018 - 2030 (USD Billion)
4.1 HRT Market: Product Movement Analysis
4.2 Estrogen & Progesterone Replacement Therapy
4.2.1 Estrogen & Progesterone replacement therapy market, 2018 - 2030 (USD Billion)
4.3 Human Growth Hormone (HGH) Replacement Therapy
4.3.1 HGH replacement therapy market, 2018 - 2030 (USD Billion)
4.4 Thyroid Hormone Replacement Therapy
4.4.1 Thyroid hormone replacement therapy market, 2018 - 2030 (USD Billion)
4.5 Testosterone Replacement Therapy
4.5.1 Testosterone replacement therapy market, 2018 - 2030 (USD Billion)
4.6 Parathyroid Hormone Replacement
4.6.1 Parathyroid Hormone Replacement market, 2018 - 2030 (USD Billion)
Chapter 5 Hormone Replacement Therapy Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Billion)
5.1 HRT Market: Route of Administration Movement Analysis
5.2 Oral
5.2.1 Oral market, 2018 - 2030 (USD Billion)
5.3 Parenteral
5.3.1 Parenteral market, 2018 - 2030 (USD Billion)
5.4 Transdermal
5.4.1 Transdermal market, 2018 - 2030 (USD Billion)
5.5 Others
5.5.1 Others market, 2018 - 2030 (USD Billion)
Chapter 6 Hormone Replacement Therapy Market - Segment Analysis, by Disease Type, 2018 - 2030 (USD Billion)
6.1 HRT Market: Disease Type Movement Analysis
6.2 Menopause
6.2.1 Menopause market, 2018 - 2030 (USD Billion)
6.3 Hypothyroidism
6.3.1 Hypothyroidism market, 2018 - 2030 (USD Billion)
6.4 Male Hypogonadism
6.4.1 Male Hypogonadism market, 2018 - 2030 (USD Billion)
6.5 Growth Hormone Deficiency
6.5.1 Growth Hormone Deficiency market, 2018 - 2030 (USD Billion)
6.6 Hypoparathyroidism
6.6.1 Hypoparathyroidism, 2018 - 2030 (USD Billion)
Chapter 7 Hormone Replacement Therapy Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)
7.1 Hormone Replacement Therapy Market, Market Share by Region, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.2.2 UK
7.1.2.2.1 UK market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.2.5 Spain
7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.2.6 Italy
7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.3 Asia-Pacific
7.1.3.1 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.3.6 South Korea
7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.4.3 Mexico
7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.4.4 Argentina
7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.5 Middle East and Africa
7.1.5.1 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.5.2 South Africa
7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
7.1.5.4 UAE
7.1.5.4.1 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 8 Hormone Replacement Therapy Market - Competitive Analysis
8.1 Major Deals and Strategic Alliances Analysis
8.1.1 New Product Launch
8.1.2 Mergers and Acquisitions
8.1.3 Partnerships and Strategic Collaborations
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Market Differentiators
8.2.2 Innovators
8.2.3 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.4 Heat map analysis
8.5 Public Companies
8.5.1 Key company market share analysis, 2021
8.5.2 Company Market Position Analysis
8.6 Private Companies
8.6.1 List of key emerging companies
8.6.2 Regional Network Map
8.7 Company Profiles
8.7.1 Bayer AG
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 Pfizer, Inc.
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.3 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Merck & Co., Inc.
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 Viatris Inc.
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 Novo Nordisk A/S
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Eli Lilly and Company
8.7.6.1 Company overview
8.7.6.2 Financial performance
8.7.6.3 Product benchmarking
8.7.6.4 Strategic initiatives
8.7.7 F. Hoffmann-La Roche Ltd. (Genentech)
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.8 Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)
8.7.8.1 Company overview
8.7.8.2 Financial performance
8.7.8.3 Product benchmarking
8.7.8.4 Strategic initiatives
8.7.9 ASCEND Therapeutics US, LLC. (Besins Healthcare)
8.7.9.1 Company overview
8.7.9.2 Product benchmarking
8.7.9.3 Strategic initiatives
8.7.10 AbbVie Inc.
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers